Introduction: A high genetic risk for obesity increases the likelihood of obesity-related diseases that is a global health issue. However, a healthy lifestyle can significantly reduce these risks, regardless of genetic predisposition.
Methods: This study utilized the NCBI database and the Mega Gene pharmacogenomics software to analyze genetic polymorphisms and identify potential side effects based on individual genetic makeup.
Results: Our analysis revealed that FTO polymorphisms were the most prevalent phenotype associated with type 2 diabetes. Subsequently, we investigated the efficacy of various weight loss medications in individuals carrying common genetic polymorphisms within the Iranian genome.
Conclusion: Genetic testing for polymorphisms in common genes like: FABP2, FTO, and MC4R polymorphisms is crucial before obesity treatment to optimize drug selection and minimize side effects.
Keywords: obesity, genetic, polymorphisms, medication, side effects